[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

BR9915460A - Método de tratamento de febre hemorrágica virótica - Google Patents

Método de tratamento de febre hemorrágica virótica

Info

Publication number
BR9915460A
BR9915460A BR9915460-9A BR9915460A BR9915460A BR 9915460 A BR9915460 A BR 9915460A BR 9915460 A BR9915460 A BR 9915460A BR 9915460 A BR9915460 A BR 9915460A
Authority
BR
Brazil
Prior art keywords
treatment
hemorrhagic fever
viral hemorrhagic
provides
toxicity
Prior art date
Application number
BR9915460-9A
Other languages
English (en)
Inventor
Charles Jack Fisher
Sau-Chi Betty Yan
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of BR9915460A publication Critical patent/BR9915460A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4866—Protein C (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Patente de Invenção: <B>"MéTODO DE TRATAMENTO DE FEBRE HEMORRáGICA VIRóTICA"<D>. A presente invenção oferece um método de tratamento de febre hemorrágica virótica com proteína C. A invenção reivindicada oferece uma terapia necessária para um distúrbio sério e debilitante ao mesmo tempo em que evita complicações tais como tendência ao sangramento, toxidez e efeitos secundários comuns dos agentes anticoagulantes atualmente disponíveis.
BR9915460-9A 1998-11-20 1999-11-15 Método de tratamento de febre hemorrágica virótica BR9915460A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10915398P 1998-11-20 1998-11-20
PCT/US1999/027074 WO2000030677A1 (en) 1998-11-20 1999-11-15 Method of treating viral hemorrhagic fever

Publications (1)

Publication Number Publication Date
BR9915460A true BR9915460A (pt) 2001-07-17

Family

ID=22326085

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9915460-9A BR9915460A (pt) 1998-11-20 1999-11-15 Método de tratamento de febre hemorrágica virótica

Country Status (12)

Country Link
US (2) US6270764B1 (pt)
EP (1) EP1131091B1 (pt)
JP (1) JP2002530353A (pt)
CN (1) CN1326356A (pt)
AT (1) ATE235915T1 (pt)
AU (1) AU2149800A (pt)
BR (1) BR9915460A (pt)
CA (1) CA2351470A1 (pt)
DE (1) DE69906568T2 (pt)
ES (1) ES2195655T3 (pt)
IL (1) IL142220A0 (pt)
WO (1) WO2000030677A1 (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9915460A (pt) * 1998-11-20 2001-07-17 Lilly Co Eli Método de tratamento de febre hemorrágica virótica
WO2002024215A2 (en) * 2000-09-18 2002-03-28 Eli Lilly And Company Method for using activated protein c for the treatment of coagulation-associated disorders
EP1446140A4 (en) 2001-10-15 2007-03-07 Novartis Vaccines & Diagnostic TREATMENT OF HEAVY PNEUMONIA BY ADMINISTRATION OF TFPI (TISSUE FACTOR PATHWAY INHIBITOR)
US7132398B2 (en) 2003-05-06 2006-11-07 Dendreon Corporation Method of treatment of hemorrhagic disease using a factor VIIa/tissue factor inhibitor
JP2007532486A (ja) * 2004-03-17 2007-11-15 カイロン コーポレイション 組織因子経路インヒビターの投与による重度の市中肺炎の処置
WO2007092607A2 (en) * 2006-02-09 2007-08-16 Genetech, Inc. Treatment of hemorrhagic viral infections using a tissue factor inhibitor
US20200093853A1 (en) * 2016-12-08 2020-03-26 Cellphire, Inc. Compositions and methods for treatment of loss of fluids leading to hypotension and/or hypovolemia
US11767511B2 (en) 2018-11-30 2023-09-26 Cellphire, Inc. Platelets as delivery agents
WO2020113090A1 (en) 2018-11-30 2020-06-04 Cellphire, Inc. Platelets as delivery agents
KR20220016092A (ko) 2019-05-03 2022-02-08 셀파이어, 인크. 혈액 생성물을 생산하기 위한 물질 및 방법
CN114450066A (zh) 2019-08-16 2022-05-06 塞尔菲乐有限公司 作为抗血小板剂逆转剂的血栓小体
US20210308185A1 (en) 2020-02-04 2021-10-07 Cellphire, Inc. Methods of treating acquired hemophilia with anti-fibrinolytic loaded platelets

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4775624A (en) 1985-02-08 1988-10-04 Eli Lilly And Company Vectors and compounds for expression of human protein C
US5516650A (en) 1985-06-27 1996-05-14 Zymogenetics, Inc. Production of activated protein C
US5550036A (en) 1986-04-09 1996-08-27 Eli Lilly And Company Method for co-amplification of human protein C genes in human cells
US4992373A (en) 1987-12-04 1991-02-12 Eli Lilly And Company Vectors and compounds for direct expression of activated human protein C
US4981952A (en) 1988-10-04 1991-01-01 Eli Lilly And Company Method for the purification of vitamin K-dependent proteins
IL97312A (en) 1990-02-23 1999-01-26 Lilly Co Eli A method of generating a polypeptide in an eukaryotic vector AND recombinant surrogate cell containing an enhanced transcriptional control unit based on the primary late adenovirus coefficient
US5506134A (en) * 1990-10-22 1996-04-09 Corvas International, Inc. Hypridoma and monoclonal antibody which inhibits blood coagulation tissue factor/factor VIIa complex
AT402262B (de) 1991-06-20 1997-03-25 Immuno Ag Arzneimittel enthaltend aktiviertes protein c
MY110664A (en) 1992-05-21 1999-01-30 Lilly Co Eli Protein c derivatives
WO1997020043A1 (en) 1995-11-30 1997-06-05 Zymogenetics, Inc. Protein c production in transgenic animals
WO1998048822A1 (en) * 1997-04-28 1998-11-05 Eli Lilly And Company Improved methods for processing activated protein c
BR9915460A (pt) * 1998-11-20 2001-07-17 Lilly Co Eli Método de tratamento de febre hemorrágica virótica
WO2000066754A1 (en) * 1999-04-30 2000-11-09 Eli Lilly And Company Protein c derivatives

Also Published As

Publication number Publication date
JP2002530353A (ja) 2002-09-17
DE69906568T2 (de) 2004-02-12
US6767539B2 (en) 2004-07-27
ATE235915T1 (de) 2003-04-15
DE69906568D1 (de) 2003-05-08
CA2351470A1 (en) 2000-06-02
US6270764B1 (en) 2001-08-07
WO2000030677A1 (en) 2000-06-02
CN1326356A (zh) 2001-12-12
IL142220A0 (en) 2002-03-10
ES2195655T3 (es) 2003-12-01
AU2149800A (en) 2000-06-13
EP1131091A1 (en) 2001-09-12
EP1131091B1 (en) 2003-04-02
US20010028880A1 (en) 2001-10-11

Similar Documents

Publication Publication Date Title
ATE234092T1 (de) 2-alkylpyrrolidine
TR200000782T2 (tr) Resorsinol türevleri.
UA34466C2 (uk) Засіб для несистемної боротьби з паразитуючими комахами
ES2184149T3 (es) Paclitaxeles 6-tio sustituidos.
TR199900083T2 (xx) Klaritromisinin kristal bi�imi I.
PE14199A1 (es) Agonistas de 5-ht1f
ES2106700T3 (es) Procedimiento para la preparacion de derivados de la 4a,5,9,10,11,12-hexahidro-6h-benzofuro(3a,3,2-ef)(2)benzacepinas.
ATE210988T1 (de) Zytotoxischer aminozucker und verwandte zuckerderivate von indolopyrrolocarbazolen
BR9915460A (pt) Método de tratamento de febre hemorrágica virótica
DK0825857T3 (da) Anvendelse af gabapentin og derivater deraf til behandling af mani og bipolær lidelse
SE9802937D0 (sv) Novel compounds
ES2088128T3 (es) Aminosulfonilureas inhibidoras de acat.
NO993407L (no) Fremstilling av proteinpreparater med nedsatt aggregatinnhold
BR9915317A (pt) Método de tratar trombocitopenia induzida por heparina
DK1133314T3 (da) Protein C til behandling af seglcellesygdom og thalassæmi
EP0116628A4 (en) 1-ACYL-3-PYRIDYLMETHYLGUANIDINE AND THEIR USE AS AN ANI-HYPERTENSIVE.
BR9915984A (pt) Método de tratar púrpura trombocitopênica e sìndrome urêmica hemolìtica
PT908107E (pt) Composicoes adocantes contendo neohesperidina-dihidrocalcona e pelo menos um outro adocante de elevada intensidade
IT1271685B (it) Impiego dei polidesossiribonucleotidi nelle neuropati diabetiche
PT1001789E (pt) Produto compreendendo pelo menos um arn de dupla helice em associacao com pelo menos um derivado do 6-benziluracilo para uma utilizacao terapeutica simultanea separada ou prolongada no tempo
UA15363A (uk) Засіб для лікуваhhя відкритих пошкоджеhь

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]